

Inventor Search

Canella 09/186, 475

12/09/2003

=> d ibib abs hitstr 110 1-3


L10 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1998:394037 HCAPLUS
DOCUMENT NUMBER: 129:36430
TITLE: Screening assays for compounds
INVENTOR(S): Hirth, Klaus Peter; App, Harald; Tsai, Jianming
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: U.S., 12 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5763198	A	19980609	US 1994-279321	19940722
PRIORITY APPLN. INFO.:			US 1994-279321	19940722

AB The invention is directed to rapid and quant. assay systems for screening test compds. for their ability to modulate tyrosine kinase or phosphatase activities involved in signal transduction by detg. the tyrosine phosphorylation state of a protein substrate using an anti-phosphotyrosine antibody and an antibody specific for the protein substrate. These assays may be practiced in a whole cell or cell-free system. The assays can be used to identify test compds. for use in therapeutic applications to disease processes in which tyrosine kinase or phosphatase activity in a signal transduction pathway contributes to a pathol. process.

IT 446-72-0, Genistein 70563-58-5, Herbimycin A
125697-92-9, Lavendustin A
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(screening assays for compds. modulating specific protein tyrosine kinase involved in signal transduction)


RN 446-72-0 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,7-dihydroxy-3-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 70563-58-5 HCAPLUS
CN Geldanamycin, 17-demethoxy-15-methoxy-11-O-methyl-, (15R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as described by E or Z.


PAGE 1-A



PAGE 1-B

 --NH_2

RN 125697-92-9 HCAPLUS
 CN Benzoic acid, 5-[(2,5-dihydroxyphenyl)methyl][(2-hydroxyphenyl)methyl]amino]-2-hydroxy- (9CI) (CA INDEX NAME)



IT 9025-75-6, Phosphoprotein phosphatase 80449-02-1,
 Protein tyrosine kinase
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
 (Biological study); PROC (Process)
 (screening assays for compds. modulating specific protein
 tyrosine kinase involved in signal transduction)

RN 9025-75-6 HCAPLUS
 CN Phosphatase, protein phosphoserine/phosphothreonine (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 80449-02-1 HCAPLUS
 CN Kinase (phosphorylating), protein (tyrosine) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 65 THERE ARE 65 CITED REFERENCES AVAILABLE FOR THIS

RECORD, ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 1997:640690 HCAPLUS
 DOCUMENT NUMBER: 127:314804
 TITLE: Assays for KDR/FLK-1 receptor tyrosine kinase inhibitors, and use of the inhibitors for treatment of vasculogenesis- and angiogenesis-related diseases
 INVENTOR(S): Hirth, Klaus P.; McMahon, Gerald; Shawver, Laura K.
 PATENT ASSIGNEE(S): Sugen, Inc., USA
 SOURCE: PCT Int. Appl., 65 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9734920	A1	19970925	WO 1997-US3378	19970304
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9720667	A1	19971010	AU 1997-20667	19970304
PRIORITY APPLN. INFO.:			US 1996-621734	19960321
			WO 1997-US3378	19970304

AB Processes are disclosed for the identification of compds. and pharmaceutical compns. capable of selectively and potently inhibiting KDR/FLK-1 tyrosine kinase signal transduction in order to inhibit vasculogenesis and/or angiogenesis. The invention also relates to compds. and compns. identified using the methods of the invention and the use thereof for the treatment of disease relating to inappropriate vasculogenesis and/or angiogenesis. The invention provides an assay cascade comprised of several "filter steps" of increasing selectivity which identify a limited subset of candidate compds. affecting the VEGF receptor on the mol. level.

IT 127464-60-2, Vascular endothelial growth factor
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (KDR/FLK-1 receptor tyrosine kinase inhibitor identification assay, and use of compds. for treatment of vasculogenesis- and angiogenesis-related diseases)

RN 127464-60-2 HCAPLUS

CN Vascular endothelial growth factor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 3359-49-7, SU 4928 5812-07-7, SU 4312 62540-08-3
 , SU 5208 91822-51-4, SU 4314 168835-82-3, SU 1498
 168835-90-3, SU 1433 186611-03-0, SU 4932
 186611-55-2, SU 4313 197592-54-4, SU 0879
 197592-55-5, SU 1076 197592-56-6, SU 1385
 197592-57-7, SU 1387 197592-58-8, SU 1393
 197592-61-3, SU 1835 197592-62-4, SU 4136
 197592-63-5, SU 4157 197592-64-6, SU 4161


197592-65-7, SU 4209 197592-66-8, SU 4304
 197592-67-9, SU 4328 197592-68-0, SU 4334
 197592-69-1, SU 4348 197592-70-4, SU 4929
 197592-71-5, SU 4936 197592-72-6, SU 4943
 197592-73-7, SU 4945 197592-74-8, SU 5014
 197592-75-9, SU 5015 204005-46-9, SU 5416

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(KDR/FLK-1 receptor tyrosine kinase inhibitor identification assay, and use of compds. for treatment of vasculogenesis- and angiogenesis-related diseases)


RN 3359-49-7 HCAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-3-(phenylmethylene)- (9CI) (CA INDEX NAME)




RN 5812-07-7 HCAPLUS

CN 2H-Indol-2-one, 3-[[4-(dimethylamino)phenyl]methylene]-1,3-dihydro- (9CI)
 (CA INDEX NAME)




RN 62540-08-3 HCAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-3-(2-thienylmethylene)- (9CI) (CA INDEX NAME)



RN 91822-51-4 HCAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)- (9CI) (CA INDEX NAME)



RN 168835-82-3 HCAPLUS


CN 2-Propenamide, 2-cyano-3-[4-hydroxy-3,5-bis(1-methylethyl)phenyl]-N-(3-phenylpropyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 168835-90-3 HCAPLUS


CN 1,2-Benzenediol, 4-(6,7-dimethyl-2-quinoxalinyl)- (9CI) (CA INDEX NAME)



RN 186611-03-0 HCAPLUS

CN 2H-Indol-2-one, 3-[(2-chloro-4-hydroxyphenyl)methylene]-1,3-dihydro- (9CI)
(CA INDEX NAME)

RN 186611-55-2 HCAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-3-[(4-(1-methylethyl)phenyl)methylene]- (9CI)
(CA INDEX NAME)

RN 197592-54-4 HCAPLUS

CN SU 0879 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 197592-55-5 HCAPLUS

CN SU 1076 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 197592-56-6 HCAPLUS

CN SU 1385 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 197592-57-7 HCAPLUS

CN SU 1387 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 197592-58-8 HCAPLUS

CN SU 1393 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 197592-61-3 HCAPLUS

CN SU 1835 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 197592-62-4 HCAPLUS

CN SU 4136 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 197592-63-5 HCAPLUS

CN SU 4157 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 197592-64-6 HCAPLUS

CN SU 4161 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 197592-65-7 HCAPLUS

CN SU 4209 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 197592-66-8 HCAPLUS

CN SU 4304 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 197592-67-9 HCAPLUS

CN SU 4328 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 197592-68-0 HCAPLUS

CN SU 4334 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 197592-69-1 HCAPLUS

CN SU 4348 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 197592-70-4 HCAPLUS

CN SU 4929 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 197592-71-5 HCAPLUS

CN SU 4936 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 197592-72-6 HCPLUS

CN SU 4943 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 197592-73-7 HCPLUS

CN SU 4945 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 197592-74-8 HCPLUS

CN SU 5014 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 197592-75-9 HCPLUS

CN SU 5015 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 204005-46-9 HCPLUS

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-(9CI) (CA INDEX NAME)



IT 141350-03-0, Flt-1 VEGF receptor tyrosine kinase

150977-45-0, Flk-1/KDR VEGF receptor tyrosine kinase

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(KDR/FLK-1 receptor tyrosine kinase inhibitor identification assay, and use of compds. for treatment of vasculogenesis- and angiogenesis-related diseases)

RN 141350-03-0 HCPLUS

CN Kinase (phosphorylating), vascular endothelial growth factor receptor, gene flt-1 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 150977-45-0 HCPLUS

CN Kinase (phosphorylating), gene flk-1 protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 60-18-4, Tyrosine, biological studies


RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(phosphorylation; KDR/FLK-1 receptor tyrosine kinase inhibitor identification assay, and use of compds. for treatment of vasculogenesis- and angiogenesis-related diseases)

RN 60-18-4 HCPLUS

CN L-Tyrosine (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L10 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 1997:145206 HCAPLUS
 DOCUMENT NUMBER: 126:139857
 TITLE: Screening assays for compounds
 INVENTOR(S): Ullrich, Axel; App, Harald; Hirth, Klaus P.;
 Tsai, Jianming
 PATENT ASSIGNEE(S): Sugen, Inc., USA
 SOURCE: PCT Int. Appl., 48 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9640276	A1	19961219	WO 1996-US8332	19960603
W: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IL, IS, JP, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, AM, AZ, BY				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9659658	A1	19961230	AU 1996-59658	19960603
EP 873142	A1	19981028	EP 1996-916950	19960603
R: CH, DE, FR, GB, IT, LI				
PRIORITY APPLN. INFO.:			US 1995-488156	19950607
			WO 1996-US8332	19960603

AB The invention is directed to rapid and quant. assay systems for screening test compds., such as drugs and ligands, for their ability to modulate tyrosine kinase or phosphotyrosine phosphatase activities involved in signal transduction. These assays involve monitoring the phosphorylation or dephosphorylation of tyrosine residues on selected substrates involved in signal transduction in a target cell and may be practiced in a whole cell or cell-free system. The assays can be used to identify compds. for use in therapeutic applications to disease processes in which tyrosine kinase or phosphatase activity in a signal transduction pathway contributes to a pathol. process, such as neoplasm, diabetes, anemia, immunodeficiency, inflammation, rheumatoid arthritis, etc.

IT 79747-53-8, Phosphotyrosine phosphatase 80449-02-1,
 Protein tyrosine kinase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (modulators; screening assays for modulators of tyrosine kinase or phosphotyrosine phosphatase activities involved in signal transduction)

RN 79747-53-8 HCAPLUS


CN Phosphatase, phosphoprotein (phosphotyrosine) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 80449-02-1 HCAPLUS
 CN Kinase (phosphorylating), protein (tyrosine) (9CI) (CA INDEX NAME)


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
 IT 446-72-0, Genistein 62996-74-1, Staurosporin
 70563-58-5, Herbimycin A 125697-92-9, Lavendustin A
 186371-06-2 186371-07-3 186371-08-4
 186371-09-5 186371-10-8 186371-11-9
 186371-12-0 186371-13-1 186371-14-2
 RL: ANT (Analyte); BAC (Biological activity or effector, except adverse);
 BSU (Biological study, unclassified); ANST (Analytical study); BIOL
 (Biological study)
 (screening assays for modulators of tyrosine kinase or
 phosphotyrosine phosphatase activities involved in signal transduction)

RN 446-72-0 HCAPLUS
 CN 4H-1-Benzopyran-4-one, 5,7-dihydroxy-3-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 62996-74-1 HCAPLUS
 CN 9,13-Epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one, 2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-11-(methylamino)-, (9S,10R,11R,13R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 70563-58-5 HCAPLUS
 CN Geldanamycin, 17-demethoxy-15-methoxy-11-O-methyl-, (15R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as described by E or Z.


PAGE 1-A




PAGE 1-B

—NH₂


RN 125697-92-9 HCAPLUS
 CN Benzoic acid, 5-[(2,5-dihydroxyphenyl)methyl][(2-hydroxyphenyl)methyl]amino]-2-hydroxy- (9CI) (CA INDEX NAME)




RN 186371-06-2 HCAPLUS
 CN 4H-1,2,4-Triazole, 3-(1-ethyl-3-methyl-1H-pyrazol-5-yl)-4-(3-methoxypropyl)-5-[(5-nitro-2-thiazolyl)thio]- (9CI) (CA INDEX NAME)




RN 186371-07-3 HCAPLUS
 CN 1H-1,2,4-Triazole, 3-(1,1-dimethylethyl)-5-[(5-nitro-2-thiazolyl)thio]-
 (9CI) (CA INDEX NAME)




RN 186371-08-4 HCAPLUS
 CN 1H-1,2,4-Triazole, 3-[(5-nitro-2-thiazolyl)thio]-5-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 186371-09-5 HCAPLUS
 CN 3H-1,2,4-Triazol-3-one, 4-cyclohexyl-2,4-dihydro-5-[(5-nitro-2-thiazolyl)thio]- (9CI) (CA INDEX NAME)



RN 186371-10-8 HCAPLUS
 CN 3H-1,2,4-Triazol-3-one, 2,4-dihydro-5-[(5-nitro-2-thiazolyl)thio]-4-phenyl-
 (9CI) (CA INDEX NAME)




RN 186371-11-9 HCAPLUS
 CN 3H-1,2,4-Triazol-3-one, 2,4-dihydro-5-[(5-nitro-2-thiazolyl)thio]-4-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 186371-12-0 HCAPLUS

CN 1H-1,2,4-Triazole, 3-[(5-nitro-2-thiazolyl)thio]-5-phenyl- (9CI) (CA INDEX NAME)




RN 186371-13-1 HCAPLUS

CN 1H-1,2,4-Triazole, 3-[(4-chlorophenyl)thio]-5-[(5-nitro-2-thiazolyl)thio]- (9CI) (CA INDEX NAME)



RN 186371-14-2 HCAPLUS

CN 3H-1,2,4-Triazol-3-one, 2,4-dihydro-5-[(5-nitro-2-thiazolyl)thio]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



IT 21820-51-9, Phosphotyrosine

RL: ANT (Analyte); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)

(screening assays for modulators of tyrosine kinase or phosphotyrosine phosphatase activities involved in signal transduction)

RN 21820-51-9 HCAPLUS

CN L-Tyrosine, dihydrogen phosphate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Canella 09/186,475

12/09/2003

